Overview

Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT

Status:
Unknown status
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
To explore the efficacy and safety of toripalimab plus stereotactic body radiotherapy for hepatocellular carcinom with portal vein tumor thrombus.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University